证券代码：300436 证券简称：广生堂 公告编号：2025067 福建广生堂药业股份有限公司 关于控股子公司签订 A 轮增资协议之补充协议（二） 暨承诺履行期限延长的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、交易概述 2023 年 1 月 5 日，福建广生堂药业股份有限公司（以下简称"公司"）召 开第四届董事会第十七次会议及第四届监事会第十六次会议，审议通过了《关于 创新药控股子公司广生中霖增资扩股暨引入投资者的议案》。福州创新创科投资 合伙企业（有限合伙）（简称"创新创科"）、宁德市汇聚一号股权投资合伙企 业（有限合伙）（简称"宁德汇聚"）及杭州泰鲲股权投资基金合伙企业（有限 合伙）（简称"杭州泰鲲"）、杭州泰誉四期创业投资合伙企业（有限合伙）（简 称"杭州泰誉四期"）合计向公司创新药子公司福建广生中霖生物科技有限公司 （简称"广生中霖"）增资 22,000 万元，各方因此签署《关于福建广生中霖生 物科技有限公司之增资协议》及《关于福建广生中霖生物科技有限公司增资协议 之补充协议》（以下简称"《补充协议（一）》"）。具体内容详见公司披露的 ...

福建广生堂药业股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召 开第五届董事会第十一次会议审议通过了《关于控股子公司股权转让及增资扩股 暨公司放弃优先权的议案》，同意公司创新药控股子公司福建广生中霖生物科技 有限公司（简称"广生中霖"）少数股东股权对外转让及广生中霖增资扩股引入 重要投资者，公司放弃优先购买权和优先认缴出资权事项，同意提请股东大会授 权管理层全权办理本次增资的后续事项，包括但不限于在权限范围内确认本次交 易相关协议的具体内容、签订协议以及具体履行协议的相关事宜。济南泰神投资 合伙企业（有限合伙）（以下简称"济南泰神"）和华欣石恒科技创业投资基金 （青岛）合伙企业（有限合伙）（简称"华欣石恒"）拟按照广生中霖投前整体 估值 25 亿元合计增资 19,135.1351 万元认购广生中霖新增注册资本 2,973.60 万元，同时广生中霖股东福州奥泰五期投资合伙企业（有限合伙）、福州奥泰六 期投资合伙企业（有限合伙）拟以广生中霖投前整体估值 17.5 亿元将各自持有 的部分广生中霖股权以合计 5,864.8649 万元进行转让。本次交易完成后，广生 中霖注册资本由 38,850 万元 ...

Market Overview - As of 10:31 AM, the Shanghai Composite Index is at 3824.75 points, with a change of 0.12% [1] - The total trading volume of A-shares today is 10110.35 billion yuan [1] Technical Analysis - A total of 85 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - The stocks with the largest distance between their 5-day and 10-day moving averages include: - Shanshui Bide: 5-day MA at 50.86 yuan, 10-day MA at 51.68 yuan, difference of -1.57% [1] - China Rare Earth: 5-day MA at 52.86 yuan, 10-day MA at 53.68 yuan, difference of -1.52% [1] - Guangsheng Tang: 5-day MA at 111.23 yuan, 10-day MA at 112.88 yuan, difference of -1.46% [1] Individual Stock Performance - Shanshui Bide: Today's change is -2.53%, with a turnover rate of 1.17% [1] - China Rare Earth: Today's change is -0.29%, with a turnover rate of 1.79% [1] - Guangsheng Tang: Today's change is -0.19%, with a turnover rate of 2.29% [1] - Other notable stocks with negative changes include: - Ningbo Fangzheng: -2.39% [1] - Hongde Co.: -1.81% [1] - Positive performers include: - Dadi Xiong: +0.37% [1] - Weilon Co.: +0.36% [1]

Meeting Details - The second extraordinary general meeting of shareholders for 2025 was held on September 17, 2025, at 14:30 [2] - The meeting combined on-site voting and online voting, with specific time slots for online voting [3][4] Attendance - A total of 417 shareholders attended the meeting, representing 66,288,792 shares, which is 41.6212% of the total shares [5] - Among them, 5 shareholders attended in person, representing 65,131,292 shares (40.8944%), while 412 shareholders participated via online voting, representing 1,157,500 shares (0.7268%) [5][6] Resolutions - The meeting approved the proposal regarding the equity transfer and capital increase of a controlling subsidiary, with 66,098,092 shares in favor (99.7123%) [8] - The minority shareholders voted 966,800 shares in favor (83.5248%) of the same proposal [9] Legal Opinion - The legal representatives from Guohao Law Firm confirmed that the meeting's procedures complied with relevant laws and regulations, and the voting results were valid [11] Documentation - The resolutions from the second extraordinary general meeting and the legal opinion from Guohao Law Firm are available for review [12]

2025 年第二次临时股东大会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 国浩律师（上海）事务所 关 于 福建广生堂药业股份有限公司 二零二五年九月 国浩律师（上海）事务所 关于福建广生堂药业股份有限公司 2025 年第二次临时股东大会之法律意见书 致：福建广生堂药业股份有限公司 福建广生堂药业股份有限公司（以下简称"公司"）2025 年第二次临时股东 大会于 2025 年 9 月 17 日召开。国浩律师（上海）事务所（以下简称"本所"） 经公司聘请，委派律师出席现场会议，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"） 等法律、法规及中国证券监督管理 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：300436 证券简称：广生堂 公告编号：2025065 福建广生堂药业股份有限公司 关于 2025 年第二次临时股东大会决议的公告 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开时间： 1、现场会议召开时间：2025 年 9 月 17 日（星期三）14:30 2、网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 17 日 9:15—9:25，9:30—11:30 和 13:00—15:00。 （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 9 月 17 日 9:15—15:00。 （二）现场会议召开地点：福建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二期 16 号楼 13F 会议室。 （三）会议召集人：公司董事会 （四）会议主持人：董事长李国平先生 （五）会议召开方式：现场表决与网络投票相结合的方式 （六）会议召 ...

Group 1 - The "Second Golden Kylin Best Investment Advisor Selection" event is currently ongoing, with over 3,000 professional investment advisors participating in simulated trading competitions [1][4] - The event aims to provide a platform for investment advisors to showcase their capabilities and enhance communication with the public, thereby promoting the healthy development of China's wealth management industry [1] Group 2 - The top 10 stocks by purchase frequency on September 17 include 华胜天成 (Huasheng Tiancai), 协创数据 (Xiechuang Data), and 绿的谐波 (Green Harmonics) [1] - The top 10 stocks by purchase amount on September 17 include 胜宏科技 (Shenghong Technology), 双环传动 (Shuanghuan Transmission), and 汉宇集团 (Hanyu Group) [2] - The data for the top purchased stocks and ETFs is based on the frequency and amount of purchases made by all participating advisors [3]

Market Overview - The Shanghai Composite Index rose by 0.37% on September 17, with 20 industries experiencing gains, led by the power equipment and automotive sectors, which increased by 2.55% and 2.05% respectively [1] - Conversely, the agriculture, forestry, animal husbandry, and fishery sectors, along with retail, saw declines of 1.02% and 0.98% respectively [1] - The pharmaceutical and biotechnology sector fell by 0.23% [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 38.306 billion yuan, with five industries seeing net inflows [1] - The power equipment sector led the net inflow with 1.835 billion yuan, followed by the automotive sector with 1.142 billion yuan [1] - The non-bank financial sector experienced the largest net outflow, totaling 5.229 billion yuan, followed by the computer sector with a net outflow of 4.455 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector saw a net outflow of 3.977 billion yuan, with 474 stocks in the sector; 135 stocks rose while 327 fell [2] - The top net inflow stocks included WuXi AppTec with 352 million yuan, followed by Hengrui Medicine and Boteng Co., with inflows of 312 million yuan and 55.426 million yuan respectively [2] - Nine stocks in the sector experienced net outflows exceeding 100 million yuan, with the largest outflows from Guangsheng Tang, Sino Medical, and Ganli Pharmaceutical, amounting to 253 million yuan, 164 million yuan, and 140 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - WuXi AppTec: +2.09%, turnover rate 2.01%, net inflow 351.585 million yuan [2] - Hengrui Medicine: +1.42%, turnover rate 0.92%, net inflow 312.024 million yuan [2] - Boteng Co.: -0.93%, turnover rate 6.09%, net inflow 55.426 million yuan [2] Top Losers in Pharmaceutical Sector - Guangsheng Tang: -4.40%, turnover rate 9.74%, net outflow -252.737 million yuan [3] - Sino Medical: -1.74%, turnover rate 5.85%, net outflow -164.152 million yuan [3] - Ganli Pharmaceutical: -1.74%, turnover rate 2.88%, net outflow -139.861 million yuan [3]

Group 1 - The "Second Golden Unicorn Best Investment Advisor Selection" event is currently ongoing, with over 3,000 professional investment advisors participating in simulated portfolio competitions [1] - The event aims to provide a platform for investment advisors to showcase their capabilities, expand services, and enhance skills, thereby promoting the healthy development of China's wealth management industry [1] Group 2 - The top ten stocks by buy volume on September 16 include: Huasheng Tiancheng, Xiechuang Data, and Green Harmony, among others [2] - The top ten stocks by buy amount on September 16 include: Shenghong Technology, Shuanghuan Transmission, and Hanyu Group, among others [3] - The data for the top buy stocks/ETFs is based on the frequency of purchases by all participating advisors, while the buy amount data reflects the top ten stocks/ETFs by total investment amount [4]

Group 1 - The core viewpoint of the news is that Guangshengtang's stock price has dropped by 5% to 114.57 CNY per share, with a trading volume of 9.67 billion CNY and a turnover rate of 6.00%, resulting in a total market capitalization of 182.47 billion CNY [1] - Guangshengtang Pharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its main business revenue coming from liver and gallbladder disease medications [1] - The company was established on June 28, 2001, and went public on April 22, 2015, located in Fuzhou, Fujian Province [1] Group 2 - Among the top ten circulating shareholders of Guangshengtang, a fund under China Europe Fund has increased its holdings by 393,100 shares, bringing its total to 1.8447 million shares, which accounts for 1.35% of the circulating shares [2] - The China Europe Medical Health Mixed A Fund (003095) has a current scale of 15.638 billion CNY and has achieved a year-to-date return of 32.89% [2] - The fund manager, Ge Lan, has a tenure of 10 years and 234 days, with the best fund return during this period being 128.39% [3]